Therapy for metastatic melanoma: an overview and update

References

• AIHW Australia Cancer Incidence and Mortality (ACIM) Books: Incidence Numbers and Rates from 1982 to 2006, and Mortality Numbers and Rates from 1968 to 2007 (2010).
   Google Scholar
• SEER Cancer Statistics Review, 1975–2005. National Cancer Institute, Bethesda, MD, USA (2008).
   Google Scholar
• Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet365(9460), 687–701 (2005).
   PubMed Web of Science ®Google Scholar
• Balch CM, Gershenwald JE, Soong SJ et al. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol.27(36), 6199–6206 (2009).
   PubMed Web of Science ®Google Scholar
• Balch CM, Soong SJ, Gershenwald JE et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J. Clin. Oncol.19(16), 3622–3634 (2001).
   PubMed Web of Science ®Google Scholar
• Carlson JA, Ross JS, Slominski A et al. Molecular diagnostics in melanoma. J. Am. Acad. Dermatol.52(5), 743–775; quiz 775–778 (2005).
   PubMedGoogle Scholar
• Elwood JM, Jopson J. Melanoma and sun exposure: an overview of published studies. Int. J. Cancer73(2), 198–203 (1997).
   PubMed Web of Science ®Google Scholar
• Goldstein AM, Tucker MA. Etiology, epidemiology, risk factors, and public health issues of melanoma. Curr. Opin. Oncol.5(2), 358–363 (1993).
   PubMedGoogle Scholar
• Veierod MB, Weiderpass E, Thorn M et al. A prospective study of pigmentation, sun exposure, and risk of cutaneous malignant melanoma in women. J. Natl Cancer Inst.95(20), 1530–1538 (2003).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr. Opin. Immunol.21(2), 233–240 (2009).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer8(4), 299–308 (2008).
   PubMed Web of Science ®Google Scholar
• Lee ML, Tomsu K, Von Eschen KB. Duration of survival for disseminated malignant melanoma: results of a meta-analysis. Melanoma Res.10(1), 81–92 (2000).
   PubMed Web of Science ®Google Scholar
• Hersey P, Bastholt L, Chiarion-Sileni V et al. Small molecules and targeted therapies in distant metastatic disease. Ann. Oncol.20(Suppl. 6), vi35–vi40 (2009).
   PubMed Web of Science ®Google Scholar
• Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N. Engl. J. Med.351(10), 998–1012 (2004).
   PubMed Web of Science ®Google Scholar
• Middleton MR, Grob JJ, Aaronson N et al. Randomized Phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J. Clin. Oncol.18(1), 158–166 (2000).
   PubMed Web of Science ®Google Scholar
• Jacquillat C, Khayat D, Banzet P et al. Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma. Cancer Chemother. Pharmacol.25(4), 263–266 (1990).
   PubMed Web of Science ®Google Scholar
• Avril MF, Aamdal S, Grob JJ et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a Phase III study. J. Clin. Oncol.22(6), 1118–1125 (2004).
   PubMed Web of Science ®Google Scholar
• Glover D, Ibrahim J, Kirkwood J et al. Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma: an Eastern Cooperative Oncology Group Study (E1686). Melanoma Res.13(6), 619–626 (2003).
   PubMed Web of Science ®Google Scholar
• Evans LM, Casper ES, Rosenbluth R. Phase II trial of carboplatin in advanced malignant melanoma. Cancer Treat. Rep.71(2), 171–172 (1987).
   PubMedGoogle Scholar
• Quagliana JM, Stephens RL, Baker LH, Costanzi JJ. Vindesine in patients with metastatic malignant melanoma: a Southwest Oncology Group study. J. Clin. Oncol.2(4), 316–319 (1984).
   PubMedGoogle Scholar
• Emmert S, Zutt M, Haenssle H, Neumann C, Kretschmer L. Inefficacy of vindesine monotherapy in advanced stage IV malignant melanoma patients previously treated with other chemotherapeutic agents. Melanoma Res.13(3), 299–302 (2003).
   PubMedGoogle Scholar
• Bedikian AY, Plager C, Papadopoulos N et al. Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma. Melanoma Res.14(1), 63–66 (2004).
   PubMedGoogle Scholar
• Aamdal S, Wolff I, Kaplan S et al. Docetaxel (Taxotere) in advanced malignant melanoma: a Phase II study of the EORTC Early Clinical Trials Group. Eur. J. Cancer30A(8), 1061–1064 (1994).
   PubMedGoogle Scholar
• Dummer R, Garbe C, Thompson JA et al. Randomized dose-escalation study evaluating peginterferon α-2a in patients with metastatic malignant melanoma. J. Clin. Oncol.24(7), 1188–1194 (2006).
   PubMed Web of Science ®Google Scholar
• McMasters KM, Edwards MJ, Ross MI et al. Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma. Ann. Surg.252(3), 460–465; discussion 465–466 (2010).
   PubMedGoogle Scholar
• Atkins MB, Lotze MT, Dutcher JP et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol.17(7), 2105–2116 (1999).
   PubMed Web of Science ®Google Scholar
• Pack GT, Miller TR. Metastatic melanoma with indeterminate primary site. Report of two instances of long-term survival. JAMA176, 55–56 (1961).
   PubMedGoogle Scholar
• Costanza ME, Nathanson L, Schoenfeld D et al. Results with methyl-CCNU and DTIC in metastatic melanoma. Cancer40(3), 1010–1015 (1977).
   PubMed Web of Science ®Google Scholar
• Avril MF, Bonneterre J, Delaunay M et al. Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma. Experience of the French Study Group. Cancer Chemother. Pharmacol.27(2), 81–84 (1990).
   PubMedGoogle Scholar
• Fletcher WS, Green S, Fletcher JR et al. Evaluation of cis-platinum and DTIC combination chemotherapy in disseminated melanoma. A Southwest Oncology Group Study. Am. J. Clin. Oncol.11(5), 589–593 (1988).
   PubMedGoogle Scholar
• Legha SS, Ring S, Papadopoulos N et al. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer64(10), 2024–2029 (1989).
   PubMed Web of Science ®Google Scholar
• Del Prete SA, Maurer LH, O’Donnell J, Forcier RJ, LeMarbre P. Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat. Rep.68(11), 1403–1405 (1984).
   PubMedGoogle Scholar
• Jilaveanu LB, Aziz SA, Kluger HM. Chemotherapy and biologic therapies for melanoma: do they work? Clin. Dermatol.27(6), 614–625 (2009).
   PubMed Web of Science ®Google Scholar
• Chapman PB, Einhorn LH, Meyers ML et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J. Clin. Oncol.17(9), 2745–2751 (1999).
   PubMed Web of Science ®Google Scholar
• Chiarion Sileni V, Nortilli R, Aversa SM et al. Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients. Melanoma Res.11(2), 189–196 (2001).
   PubMed Web of Science ®Google Scholar
• Perez DG, Suman VJ, Fitch TR et al. Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A. Cancer115(1), 119–127 (2009).
   PubMed Web of Science ®Google Scholar
• Bajetta E, Di Leo A, Zampino MG et al. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon α-2a in the treatment of advanced melanoma. J. Clin. Oncol.12(4), 806–811 (1994).
   PubMed Web of Science ®Google Scholar
• Young AM, Marsden J, Goodman A, Burton A, Dunn JA. Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-α (IFN-α) in metastatic melanoma. Clin. Oncol. (R. Coll. Radiol.)13(6), 458–465 (2001).
   PubMed Web of Science ®Google Scholar
• Dummer R, Gore ME, Hancock BW et al. A multicenter Phase II clinical trial using dacarbazine and continuous infusion interleukin-2 for metastatic melanoma. Clinical data and immunomonitoring. Cancer75(4), 1038–1044 (1995).
   PubMed Web of Science ®Google Scholar
• Eton O, Legha SS, Bedikian AY et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a Phase III randomized trial. J. Clin. Oncol.20(8), 2045–2052 (2002).
   PubMed Web of Science ®Google Scholar
• Atkins MB, Hsu J, Lee S et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon α-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J. Clin. Oncol.26(35), 5748–5754 (2008).
   PubMed Web of Science ®Google Scholar
• Atzpodien J, Neuber K, Kamanabrou D et al. Combination chemotherapy with or without s.c. IL-2 and IFN-α: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM). Br. J. Cancer86(2), 179–184 (2002).
   PubMed Web of Science ®Google Scholar
• Weinstein IB. Cancer. Addiction to oncogenes: the Achilles heal of cancer. Science297(5578), 63–64 (2002).
   PubMed Web of Science ®Google Scholar
• Curtin JA, Fridlyand J, Kageshita T et al. Distinct sets of genetic alterations in melanoma. N. Engl. J. Med.353(20), 2135–2147 (2005).
   PubMed Web of Science ®Google Scholar
• Van Raamsdonk CD, Bezrookove V, Green G et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature457(7229), 599–602 (2009).
   PubMed Web of Science ®Google Scholar
• Van Raamsdonk CD, Griewank KG, Crosby MB et al. Mutations in GNA11 in uveal melanoma. N. Engl. J. Med.363(23), 2191–2199 (2010).
   PubMed Web of Science ®Google Scholar
• Cronin JC, Wunderlich J, Loftus SK et al. Frequent mutations in the MITF pathway in melanoma. Pigment Cell Melanoma Res.22(4), 435–444 (2009).
   PubMed Web of Science ®Google Scholar
• Prickett TD, Agrawal NS, Wei X et al. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat. Genet.41(10), 1127–1132 (2009).
   PubMed Web of Science ®Google Scholar
• Yarden Y, Kuang WJ, Yang-Feng T et al. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J.6(11), 3341–3351 (1987).
   PubMed Web of Science ®Google Scholar
• Chabot B, Stephenson DA, Chapman VM, Besmer P, Bernstein A. The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature335(6185), 88–89 (1988).
   PubMed Web of Science ®Google Scholar
• Spritz RA, Giebel LB, Holmes SA. Dominant negative and loss of function mutations of the c-kit (mast/stem cell growth factor receptor) proto-oncogene in human piebaldism. Am. J. Hum. Genet.50(2), 261–269 (1992).
   PubMed Web of Science ®Google Scholar
• Lassam N, Bickford S. Loss of c-kit expression in cultured melanoma cells. Oncogene7(1), 51–56 (1992).
   PubMedGoogle Scholar
• Huang S, Luca M, Gutman M et al. Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential. Oncogene13(11), 2339–2347 (1996).
   PubMed Web of Science ®Google Scholar
• Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol.24(26), 4340–4346 (2006).
   PubMed Web of Science ®Google Scholar
• Ugurel S, Hildenbrand R, Zimpfer A et al. Lack of clinical efficacy of imatinib in metastatic melanoma. Br. J. Cancer92(8), 1398–1405 (2005).
   PubMed Web of Science ®Google Scholar
• Wyman K, Atkins MB, Prieto V et al. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer106(9), 2005–2011 (2006).
   PubMed Web of Science ®Google Scholar
• Kim KB, Eton O, Davis DW et al. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br. J. Cancer99(5), 734–740 (2008).
   PubMed Web of Science ®Google Scholar
• Lutzky J, Bauer J, Bastian BC. Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res.21(4), 492–493 (2008).
   PubMed Web of Science ®Google Scholar
• Hodi FS, Friedlander P, Corless CL et al. Major response to imatinib mesylate in KIT-mutated melanoma. J. Clin. Oncol.26(12), 2046–2051 (2008).
   PubMed Web of Science ®Google Scholar
• Fisher DE, Barnhill R, Hodi FS et al. Melanoma from bench to bedside: meeting report from the 6th International Melanoma Congress. Pigment Cell Melanoma Res.23(1), 14–26 (2010).
   PubMedGoogle Scholar
• Quintas-Cardama A, Lazar AJ, Woodman SE et al. Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nat. Clin. Pract. Oncol.5(12), 737–740 (2008).
   PubMedGoogle Scholar
• Woodman SE, Trent JC, Stemke-Hale K et al. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol. Cancer Ther.8(8), 2079–2085 (2009).
   PubMed Web of Science ®Google Scholar
• Schittenhelm MM, Shiraga S, Schroeder A et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res.66(1), 473–481 (2006).
   PubMed Web of Science ®Google Scholar
• Kluger HM, Dudek AZ, McCann C et al. A Phase 2 trial of dasatinib in advanced melanoma. Cancer DOI: 10.1002/cncr.25766 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Chin L, Garraway LA, Fisher DE. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev.20(16), 2149–2182 (2006).
   PubMed Web of Science ®Google Scholar
• Hocker T, Tsao H. Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Hum. Mutat.28(6), 578–588 (2007).
   PubMed Web of Science ®Google Scholar
• Whitwam T, Vanbrocklin MW, Russo ME et al. Differential oncogenic potential of activated RAS isoforms in melanocytes. Oncogene26(31), 4563–4570 (2007).
   PubMed Web of Science ®Google Scholar
• Sweet RW, Yokoyama S, Kamata T et al. The product of ras is a GTPase and the T24 oncogenic mutant is deficient in this activity. Nature311(5983), 273–275 (1984).
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Niedzwiecki D, Johnson J et al. Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma: CALGB 500104. J. Clin. Oncol. (Meeting Abstracts)24(18 Suppl.), 8014 (2006).
   Google Scholar
• Haluska FG, Tsao H, Wu H et al. Genetic alterations in signaling pathways in melanoma. Clin. Cancer Res.12(7 Pt 2), 2301s-7s (2006).
   PubMed Web of Science ®Google Scholar
• Stahl JM, Cheung M, Sharma A et al. Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res.63(11), 2881–2890 (2003).
   PubMed Web of Science ®Google Scholar
• Wu H, Goel V, Haluska FG. PTEN signaling pathways in melanoma. Oncogene22(20), 3113–3122 (2003).
   PubMed Web of Science ®Google Scholar
• Mirmohammadsadegh A, Marini A, Nambiar S et al. Epigenetic silencing of the PTEN gene in melanoma. Cancer Res.66(13), 6546–6552 (2006).
   PubMed Web of Science ®Google Scholar
• Tsao H, Goel V, Wu H, Yang G, Haluska FG. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J. Invest. Dermatol.122(2), 337–341 (2004).
   PubMed Web of Science ®Google Scholar
• Goel VK, Lazar AJ, Warneke CL, Redston MS, Haluska FG. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J. Invest. Dermatol.126(1), 154–160 (2006).
   PubMed Web of Science ®Google Scholar
• Curtin JA, Stark MS, Pinkel D, Hayward NK, Bastian BC. PI3-kinase subunits are infrequent somatic targets in melanoma. J. Invest. Dermatol.126(7), 1660–1663 (2006).
   PubMed Web of Science ®Google Scholar
• Davies MA, Stemke-Hale K, Tellez C et al. A novel AKT3 mutation in melanoma tumours and cell lines. Br. J. Cancer99(8), 1265–1268 (2008).
   PubMed Web of Science ®Google Scholar
• Davies MA, Stemke-Hale K, Lin E et al. Integrated molecular and clinical analysis of AKT activation in metastatic melanoma. Clin. Cancer Res.15(24), 7538–7546 (2009).
   PubMed Web of Science ®Google Scholar
• Margolin K, Longmate J, Baratta T et al. CCI-779 in metastatic melanoma: a Phase II trial of the California Cancer Consortium. Cancer104(5), 1045–1048 (2005).
   PubMed Web of Science ®Google Scholar
• Rao RD, Allred JB, Windschitl HE et al. N0377: results of NCCTG Phase II trial of the mTOR inhibitor RAD-001 in metastatic melanoma. J. Clin. Oncol. (Meeting Abstracts)25(18 Suppl.), 8530 (2007).
   Web of Science ®Google Scholar
• O’Reilly KE, Rojo F, She QB et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res.66(3), 1500–1508 (2006).
   PubMed Web of Science ®Google Scholar
• Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J. Clin. Oncol.28(6), 1075–1083 (2010).
   PubMed Web of Science ®Google Scholar
• Ihle NT, Lemos R Jr, Wipf P et al. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res.69(1), 143–150 (2009).
   PubMed Web of Science ®Google Scholar
• Jaiswal BS, Janakiraman V, Kljavin NM et al. Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors. PLoS One4(5), e5717 (2009).
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature417(6892), 949–954 (2002).
   PubMed Web of Science ®Google Scholar
• Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat. Rev. Mol. Cell. Biol.5(11), 875–885 (2004).
   PubMed Web of Science ®Google Scholar
• Wellbrock C, Hurlstone A. BRAF as therapeutic target in melanoma. Biochem. Pharmacol.80(5), 561–567 (2010).
   PubMed Web of Science ®Google Scholar
• Wan PT, Garnett MJ, Roe SM et al. Mechanism of activation of the RAF–ERK signaling pathway by oncogenic mutations of B-RAF. Cell116(6), 855–867 (2004).
   PubMed Web of Science ®Google Scholar
• Pollock PM, Harper UL, Hansen KS et al. High frequency of BRAF mutations in nevi. Nat. Genet.33(1), 19–20 (2003).
   PubMed Web of Science ®Google Scholar
• Heidorn SJ, Milagre C, Whittaker S et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell140(2), 209–221 (2010).
   PubMed Web of Science ®Google Scholar
• Garnett MJ, Rana S, Paterson H, Barford D, Marais R. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol. Cell20(6), 963–969 (2005).
   PubMed Web of Science ®Google Scholar
• Dumaz N, Hayward R, Martin J et al. In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res.66(19), 9483–9491 (2006).
   PubMed Web of Science ®Google Scholar
• Montagut C, Sharma SV, Shioda T et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res.68(12), 4853–4861 (2008).
   PubMed Web of Science ®Google Scholar
• Smalley KS, Xiao M, Villanueva J et al. CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene28(1), 85–94 (2009).
   PubMed Web of Science ®Google Scholar
• Karasarides M, Chiloeches A, Hayward R et al. B-RAF is a therapeutic target in melanoma. Oncogene23(37), 6292–6298 (2004).
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L et al. BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res.64(19), 7099–7109 (2004).
   PubMed Web of Science ®Google Scholar
• Eisen T, Ahmad T, Flaherty KT et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br. J. Cancer95(5), 581–586 (2006).
   PubMed Web of Science ®Google Scholar
• McDermott DF, Sosman JA, Gonzalez R et al. Double-blind randomized Phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J. Clin. Oncol.26(13), 2178–2185 (2008).
   PubMed Web of Science ®Google Scholar
• Hauschild A, Agarwala SS, Trefzer U et al. Results of a Phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J. Clin. Oncol.27(17), 2823–2830 (2009).
   PubMed Web of Science ®Google Scholar
• Ramurthy S, Subramanian S, Aikawa M et al. Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors. J. Med. Chem.51(22), 7049–7052 (2008).
   PubMed Web of Science ®Google Scholar
• Schwartz GK, Robertson S, Shen A et al. A Phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (pts) with advanced solid tumors. J. Clin. Oncol. (Meeting Abstracts)27(15S), 3513 (2009).
   Web of Science ®Google Scholar
• King AJ, Patrick DR, Batorsky RS et al. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res.66(23), 11100–11105 (2006).
   PubMed Web of Science ®Google Scholar
• Kefford R, Arkenau H, Brown MP et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J. Clin. Oncol. (Meeting Abstracts)28(15 Suppl.), 8503 (2010).
   Web of Science ®Google Scholar
• Long GV, Kefford RF, Carr PJ et al. Phase 1/2 study of GSK2118436, a selective inhibitor of V600 mutant (mut) BRAF kinase: evidence of activity in melanoma brain metastases (mets). Ann. Oncol.21(Suppl. 8), LBA27 (2010).
   Google Scholar
• Tsai J, Lee JT, Wang W et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl Acad. Sci. USA105(8), 3041–3046 (2008).
   PubMed Web of Science ®Google Scholar
• Flaherty K, Puzanov I, Sosman J et al. Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J. Clin. Oncol. (Meeting Abstracts)27(15S), 9000 (2009).
   Web of Science ®Google Scholar
• Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med.363(9), 809–819 (2010).
   PubMed Web of Science ®Google Scholar
• Johannessen CM, Boehm JS, Kim SY et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature468(7326), 968–972 (2010).
   PubMed Web of Science ®Google Scholar
• Nazarian R, Shi H, Wang Q et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature468(7326), 973–977 (2010).
   PubMed Web of Science ®Google Scholar
• Villanueva J, Vultur A, Lee JT et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell18(6), 683–695 (2010).
   PubMed Web of Science ®Google Scholar
• Halaban R, Zhang W, Bacchiocchi A et al. PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res.23(2), 190–200 (2010).
   PubMed Web of Science ®Google Scholar
• Solit DB, Garraway LA, Pratilas CA et al.BRAF mutation predicts sensitivity to MEK inhibition. Nature439(7074), 358–362 (2006).
   PubMed Web of Science ®Google Scholar
• Lorusso PM, Adjei AA, Varterasian M et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J. Clin. Oncol.23(23), 5281–5293 (2005).
   PubMed Web of Science ®Google Scholar
• LoRusso PM, Krishnamurthi SS, Rinehart JJ et al. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin. Cancer Res.16(6), 1924–1937 (2010).
   PubMed Web of Science ®Google Scholar
• Adjei AA, Cohen RB, Franklin W et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J. Clin. Oncol.26(13), 2139–2146 (2008).
   PubMed Web of Science ®Google Scholar
• Banerji U, Camidge DR, Verheul HM et al. The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a Phase I open-label multicenter trial in patients with advanced cancer. Clin. Cancer Res.16(5), 1613–1623 (2010).
   PubMed Web of Science ®Google Scholar
• Dummer R, Robert C, Chapman PB et al. AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: an open-label, randomized, multicenter, Phase II study. J. Clin. Oncol. (Meeting Abstracts)26(15 Suppl.), 9033 (2008).
   Web of Science ®Google Scholar
• Emery CM, Vijayendran KG, Zipser MC et al.MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc. Natl Acad. Sci. USA106(48), 20411–20416 (2009).
   PubMed Web of Science ®Google Scholar
• Ladanyi A, Kiss J, Somlai B et al. Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol. Immunother.56(9), 1459–1469 (2007).
   PubMed Web of Science ®Google Scholar
• Davis ID, Brady B, Kefford RF et al. Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a Phase IIa trial. Clin. Cancer Res.15(6), 2123–2129 (2009).
   PubMed Web of Science ®Google Scholar
• Contardi E, Palmisano GL, Tazzari PL et al. CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int. J. Cancer117(4), 538–550 (2005).
   PubMed Web of Science ®Google Scholar
• Weber J. Immune checkpoint proteins: a new therapeutic paradigm for cancer: preclinical background: CTLA-4 and PD-1 blockade. Semin. Oncol.37(5), 430–439 (2010).
   PubMed Web of Science ®Google Scholar
• Downey SG, Klapper JA, Smith FO et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin. Cancer Res.13(22 Pt 1), 6681–6688 (2007).
   PubMed Web of Science ®Google Scholar
• Hersh EM, Weber JS, Powderly JD et al. Disease control and long-term survival in chemotherapy-naive patients with advanced melanoma treated with ipilimumab (MDX- 010) with or without dacarbazine. J. Clin. Oncol. (Meeting Abstracts)26(15 Suppl.), 9022 (2008).
   Google Scholar
• Beck KE, Blansfield JA, Tran KQ et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J. Clin. Oncol.24(15), 2283–2289 (2006).
   PubMed Web of Science ®Google Scholar
• O’Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med.363(8), 711–723 (2010).
   PubMedGoogle Scholar
• Garber K. Industry makes strides in melanoma. Nat. Biotechnol.28(8), 763–764 (2010).
   PubMedGoogle Scholar
• Camacho LH, Antonia S, Sosman J et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J. Clin. Oncol.27(7), 1075–1081 (2009).
   PubMed Web of Science ®Google Scholar
• Ribas A, Hauschild A, Kefford R et al. Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. J. Clin. Oncol. (Meeting Abstracts)26(15 Suppl.), LBA9011 (2008).
   Google Scholar
• Brahmer JR, Drake CG, Wollner I et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol.28(19), 3167–3175 (2010).
   PubMed Web of Science ®Google Scholar
• Pleasance ED, Cheetham RK, Stephens PJ et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature463(7278), 191–196 (2010).
   PubMed Web of Science ®Google Scholar
• Montagut C, Sharma SV, Shioda T et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res.68(12), 4853–4861 (2008).
   PubMed Web of Science ®Google Scholar
• Emery CM, Vijayendran KG, Zipser MC et al.MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc. Natl Acad. Sci. USA106(48), 20411–20416 (2009).
   PubMed Web of Science ®Google Scholar
• Paraiso KH, Fedorenko IV, Cantini LP et al. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br. J. Cancer102(12), 1724–1730 (2010).
   PubMed Web of Science ®Google Scholar